key: cord-0729654-zcxjc1li authors: Agusti, Alvar; Sibila, Oriol; Casas-Recasens, Sandra; Mendoza, Nuria; Perea, Lidia; Lopez-Giraldo, Alejandra; Faner, Rosa title: Molecular Interactions of SARS-CoV-2 in Lung Tissue of Patients with Chronic Obstructive Pulmonary Disease date: 2021-03-30 journal: Annals of the American Thoracic Society DOI: 10.1513/annalsats.202006-619rl sha: 2b65e210a6007df5c632033c0b88050eaf02ad36 doc_id: 729654 cord_uid: zcxjc1li nan Microarray preprocessing of each data set has been previously described (14) . Observations in the LT-BCN were validated by using data from the Lung Tissue Research Consortium (LTRC), which were downloaded from the GEO (identifier GSE47460). We used linear regression (adjustment for sex because the angiotensin-converting enzyme gene is located in the X chromosome) to identify genes associated with forced expiratory volume in 1 second (FEV 1 ) % predicted. The enrichment was tested by using a hypergeometric test (GeneOverlap package for R [R Foundations for Statistical Computing]). All analyses were performed by using R. In former smokers with COPD included in LT-BCN, the level of ACE2 expression was negatively correlated with that of the FEV 1 % predicted, and this was reproduced in the LTRC (Figures 1A and 1B) . In the LT-BCN, neither use of ICS (in 42% of the patients) nor cumulative smoking exposure (pack-years) influenced ACE2 expression significantly (false discovery rate P values = 0.687 and 0.999, respectively). These data were not available in the GEO for the LTRC. Finally, in the LTRC data, increased ACE2 expression was also observed in patients with COPD compared with nonsmoker control subjects ( Figure 1B) ; the latter were not included in the LT-BCN. Next, we assessed how many of the reported SARS-CoV-2 host PPI genes (13) were differentially expressed in relation to the presence of COPD or the severity of airflow limitation. We found that in the LTRC, 18 SARS-CoV-2 host PPI genes were differentially expressed in patients with COPD compared with nonsmoker control subjects (ACE2, AP2A2, ATP1B1, CIT, DCAF7, ERMP1, FAM98A, GDF15, GNB1, IDE, LOX, NPTX1, PUSL1, SIRT5, TAPT1, TMED5, TMPRSS2, USP54, and WFS1). We could not contrast these observations with the LT-BCN because it only includes patients with COPD; in the LT-BCN, 1,249 genes were significantly related to the FEV 1 % predicted, 31 of which belong to the SARS-CoV-2 PPI network. Likewise, in the LTRC, 2,993 genes were also significantly related to the FEV 1 % predicted, 34 of which also belong to the SARS-CoV-2 PPI network. Finally, four of these identified genes (ACE2, FAM98A, MFGE8, and HMOX1) were differentially expressed in both the LT-BCN and the LTRC, and when we assessed the presence of an overall enrichment of the PPI network in relation with the severity of airflow limitation FEV 1 % predicted,weonly observed a significant enrichment for the LT-BCN (overlapping P value = 1.8 3 10 212 ; odds ratio, 4.9). This is the first study that explores how the SARS-CoV-2-human PPI network (13) changes in relation to the presence of COPD, the COPD severity (as determined by the FEV 1 % predicted), and the cumulative exposure to smoking and/or use of ICS. Results confirmed those of previous studies showing that lung ACE2 expression is upregulated in COPD (5, 6). We extended these previous observations by showing that ACE2 expression was related to the severity of airflow limitation but was not related to smoking history and/or use of ICS. Of note, very recently, the lack of an association between serum and lung levels of ACE2 has been reported (15) . Finally, our study identified three additional SARS-CoV-2 PPI genes (FAM98A, MFGE8, and HMOX1) that were differentially expressed in relation to the severity of airflow limitation in the lung tissue of patients with COPD. Interestingly, two of them (ACE2 and HMOX1) are implicated in the regulation of vasodilation, and aside from this, the HMOX1 gene encodes a heme oxygenase that is an essential enzyme in heme catabolism, which in turn induces ferritin. Ferritin has been identified in many previous studies as a marker of COVID-19 severity. Unfortunately, we lack information on circulating ferritin levels in the patients with COPD studied here. In any case, altogether, these results contribute to a better understanding of the molecular relationships between COVID-19 and COPD. Author disclosures are available with the text of this letter at www.atsjournals.org. Acknowledgment: The authors thank the participating patients for their willingness to contribute to medical research and thank the technical laboratory workers (Tamara Garcia, Gemma Sunyer) for the excellent quality of their daily work. Elexacaftor/tezacaftor/ivacaftor (E/T/I) treats nearly 90% of people with cystic fibrosis (CF) with clinically meaningful results in lung function, weight, and patient-reported outcomes. We wished to further characterize short-and long-term outcomes associated with E/T/I in this population. This retrospective study evaluates clinical outcomes over 1 year of E/T/I administration in patients with forced expiratory volume in 1 second (FEV 1 ) % predicted ,40. This is a retrospective cohort study at the adult CF program at Columbia University Irving Medical Center. The study was approved by the Institutional Review Board and via email communication with Vertex Pharmaceuticals, Inc. Patients were included if they had at least one F508del (F) mutation, initiated E/T/I between August and December SEMI-COVID-19 Network. Clinical Characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2 COPD & COVID-19 Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 Age-dependent assessment of genes involved in cellular senescence, telomere, and mitochondrial pathways in human lung tissue of smokers, COPD, and IPF: associations with SARS-CoV-2 COVID-19 ACE2-TMPRSS2-furin-DPP4 axis Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells Inhaled corticosteroids and COVID-19 risk and mortality: a nationwide cohort study A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Network analysis of lung transcriptomics reveals a distinct B-cell signature in emphysema ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study